Diabetic Macular Edema (DME) Completed Phase Trials for Bevacizumab (DB00112)

Also known as: Diabetic Macular Edema(DME) / Diabetic Macular Oedema / Macular Edema, Diabetic / Diabetic Macular Edema / Macular edema due to diabetes mellitus (disorder) / Diabetic retinal oedema / Diabetic retinal edema

IndicationStatusPhase
DBCOND0060562 (Diabetic Macular Edema (DME))CompletedNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05080803Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome
NCT03974425One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to BevacizumabTreatment
NCT02796183The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular EdemaTreatment
NCT02310295Prospective, Randomized Clinical Trial Comparing Macular Photocoagulation With or Without Intravitreal Bevacizumab or Triamcinolone for the Treatment of Diabetic Macular EdemaTreatment
NCT01640171Anesthesia Preference for Intravitreal Injection: Topical or SubconjunctivalTreatment
NCT01473251Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular DegenerationHealth Services Research